Blood-pressure-lowering treatment [1] (multiple letters)

Lancet

Volumn 357, Issue 9257, 2001, Pages 715-718

  Palmer, Christopher R ^a   Brown, Morris J ^a   Fournier, A ^b   Mazouz, H ^h   Oprisiu, R ^h   Achard, J M ^h   Fernandez, L ^h   Opie, Lionel H ^c   Kausar, Shahid A ^d   Shlipak, Michael G ^e   Hulley, Stephen B ^e   Faich, Gerald A ^f   Makuch, Robert ^g  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b AMIENS UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d St Martins Hospital   (United Kingdom)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Pharmaceutical Safety Assessments Inc   (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h School of Medicine ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; RAMIPRIL; THIAZIDE DIURETIC AGENT; VERAPAMIL;

ASIAN; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DYSLIPIDEMIA; HEART FAILURE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LETTER; META ANALYSIS; NEGRO; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; EPIDEMIOLOGY; NOTE; STATISTICAL ANALYSIS;

ANTIHYPERTENSIVE AGENTS; BIAS (EPIDEMIOLOGY); CALCIUM CHANNEL BLOCKERS; DATA INTERPRETATION, STATISTICAL; HUMANS; HYPERTENSION; META-ANALYSIS;

EID: 0035799173     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)04146-5     Document Type: Letter

References (0)